The European Council guidelines clearly provide such transition arrangements, which should be in the interest of the EU. But according to the European Commission, it is still “too early” for this discussion.
A UK spokesperson told EURACTIV.com, “We have been clear about our desire to retain a close working partnership on medicines regulation after the UK leaves the EU.”
“As we move to our future partnership, we are proposing a time-limited implementation period where we continue to have access to one another’s markets on current terms,” the UK official emphasised.
Previously, the associations representing the European and British life science industry, such as the European Federation of Pharmaceutical Industries and Associations (EFPIA), Association of the British Pharmaceutical Industry (ABPI), EuropaBio and Medicines for Europe, issued a joint statement noting it was important to secure cooperation between the UK and EU on medicines regulation.